Gardner, Mass. (PRWEB) June 25, 2008
New England Peptide, LLC (NEP), has engaged Denis Dalton as a business development manager.
Based in Toronto, Dalton will service a territory that comprises the eastern and southern United States as well as Canada, including all major biopharmaceutical hubs in the areas. In addition, he handles selected west coast and European accounts.
Dalton has more than a decade of sales and business development expertise in the biotech and chemical industries. Most recently, he served as business development manager for Debro Chemicals & Pharmaceuticals (Brampton, Ontario), where he achieved significant increases in sales and headed the company's work in handling controlled drug shipments to Canada.
Previously, Dalton managed business development relationships with major pharmaceutical and biotechnology companies, covering Canada and the United States, as territory manager for Dalton Chemical Laboratories, Inc. (Toronto). He also has held the position of sales representative for Anachemia Science (Lachine, Quebec).
Dalton holds an Honours Bachelor of Science degree in organic chemistry and microbiology from Trent University (Peterborough, Ontario), and is fluent in French and English.
"Denis' training in organic chemistry, and experience with peptides, position him to add significant value to the NEP team," says Dave Robinson, NEP's CEO. "He will be able to meet the needs of our customers at a scientific as well as service level - a trait consistent with the entire NEP business development team."
New England Peptide (http://www.newenglandpeptide.com), founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug and vaccine discovery organizations worldwide. Headquartered in the Boston metro area in Gardner, Mass., the company's chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications.
Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity, and HIV/AIDS. Peptides' inherent low toxicity and high potency, coupled with improved drug delivery methods and enhanced manufacturing capabilities, are fueling a surge in research and clinical use. All segments of the peptide market - from therapeutics and vaccines to diagnostics and cosmetics - are thriving.